Notes that the U.S. Postal Service as Express Mail, Airbill No. EU098495626US, in an envelope addressed to: Box Non-Fee Amendment, Commissioner for Patents, that shington, DC 20231, on the date shown below.

ated: January 21, 2003

Docket No.: HO-P01949US1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Frank M. Orson, et al.

Application No.: 09/827,688

Filed: April 6, 2001

For: MACROAGGREGATED PROTEIN CONJUGATES AS ORAL GENETIC IMMUNIZATION DELIVERY AGENTS Group Art Unit: 1636

Examiner: Q. Nguyen

TRANSMITTAL LETTER

RECEIVED

JAN 24 2003

TECH CENTER 1600/2500

Box Non-Fee Amendment Commissioner for Patents Washington, DC 20231

Dear Sir:

Enclosed are the following items for filing in connection with the above-referenced Patent Application:

- Amendment (16 pages) 1.
- Copy of Dictionary pages 2.
- Return Postcard 3.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. 10004014.

Dated: January 21, 2003

Respectfully submitted,

Melissa W. Acosta

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100 Houston, Texas 77010-3095

(713) 651-5151



I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU098495626US, in an envelope tabdressed to: Box Non-Fee Amendment, Commissioner for Patents, Washington, DC 20231, on the date shown below.

ated: January 21, 2003

Signature:

Docket No.: HO-P01949US1 (PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Frank M. Orson, et al.

Application No.: 09/827,688

Filed: April 6, 2001

For: MACROAGGREGATED PROTEIN CONJUGATES AS ORAL GENETIC

IMMUNIZATION DELIVERY AGENTS

Group Art Unit: 1636

Examiner: Q. Nguyen

RECEIVED

TECH CENTER 1600/2900

## **AMENDMENT**

**Box Non-Fee Amendment** Commissioner for Patents Washington, DC 20231

Dear Sir:

In response to the Office Action dated October 23, 2002 (Paper No. 7), please amend the above-identified U.S. patent application as follows:

## In the Specification

Please replace the paragraph numbered [0086], starting on page 16, line 6 of the specification, with the below paragraph.



[0086] The following polynucleotide sequences are representative sequences corresponding to HIV, HSV, HCV, influenza virus or RSV genomes or fragments of the genomes and are within the scope of the invention and some are referenced with the corresponding GenBank Accession Numbers: U23 (SEQ.ID.NO:1); AF041850: SHIV-HXBc2P 3.2, complete (SEQ.ID.NO:3); U12055: HIV-1, isolate LW12.3, lab worker, complete genome (SEQ.ID.NO:4); M76764: SHIV clone 1A11, complete genome (SEQ.ID.NO:5); NC\_001433: Hepatitis C virus, complete genome (SEQ.ID.NO:6); AF290978: Hepatitis C virus isolate colonel complete genome (SEQ.ID.NO:7); NC\_001798: Human herpesvirus 2, complete genome (SEQ.ID.NO:8); NC\_001781: Human respiratory